Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies

被引:0
作者
Luong, Huyen Thuc Tran [1 ,2 ]
Vercammen, Sofie [3 ]
de Marco, Ario [4 ]
de Rooster, Hilde [3 ]
Cosma, Antonio [1 ]
机构
[1] Luxembourg Inst Hlth, Natl Cytometry Platform, Translat Med Operat Hub, Esch Sur Alzette, Luxembourg
[2] Univ Luxembourg, Fac Sci Technol & Med, Esch Sur Alzette, Luxembourg
[3] Univ Ghent, Fac Vet Med, Small Anim Dept, Ghent, Belgium
[4] Univ Nova Gorica, Lab Environm & Life Sci, Nova Gorica, Slovenia
关键词
angiosarcoma; biomarkers; genetic alterations; metabolic pathway; protein; diagnosis; prognosis; therapeutic strategies; ENDOTHELIAL GROWTH-FACTOR; ATYPICAL VASCULAR-LESIONS; TRANSCRIPTION FACTOR ERG; EUROPAEUS-I LECTIN; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR GENE; VIII-RELATED ANTIGEN; CUTANEOUS ANGIOSARCOMA; SOFT-TISSUE; PHASE-II;
D O I
10.3389/fonc.2025.1623327
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiosarcoma is a rare, aggressive vascular malignancy characterized by rapid proliferation, early metastasis, and limited therapeutic options, resulting in poor prognosis. The etiopathogenesis of AS remains elusive and diagnosis is challenging due to its similarity to other vascular lesions. This systematic review aims to synthesize existing literature on biomarkers in human AS tissue, encompassing genomic alterations, metabolic pathway changes, specific protein, and their implications for diagnosis, prognosis, and therapy. Eighty-seven studies were identified as meeting predefined eligibility criteria following a systematic search of Pubmed and Embase between 1996 and 2024. The review highlights recurrent mutations (e.g., TP53, POT1, MYC, PTPRB, KDR), altered metabolic pathways (VEGF, ANGPT-TIE, PI3K/Akt/mTOR, MAPK/ERK), and diverse protein expression patterns (e.g., ERG, CD31, CD34, vWF). These biomarkers underscore the complex molecular landscape of AS and offer potential targets for improved diagnostic, prognostic, and therapeutic strategies. This review provides a foundation for further research and the development of novel diagnostic and therapeutic approaches for this challenging malignancy.
引用
收藏
页数:26
相关论文
共 260 条
[1]   A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma [J].
Abada, Evi ;
Jang, Hyejeong ;
Kim, Seongho ;
Ali-Fehmi, Rouba ;
Bandyopadhyay, Sudeshna .
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2022, 56 (06) :342-353
[2]   Sporadic cutaneous angiosarcomas generally lack hypoxia-inducible factor 1α: a histologic and immunohistochemical study of 45 cases [J].
Abedalthagafi, Malak ;
Rushing, Elisabeth J. ;
Auerbach, Aaron ;
Desouki, Mohamed M. ;
Marwaha, Jason ;
Wang, Zengfeng ;
Fanburg-Smith, Julie C. .
ANNALS OF DIAGNOSTIC PATHOLOGY, 2010, 14 (01) :15-22
[3]   The oncogene ERG: a key factor in prostate cancer [J].
Adamo, P. ;
Ladomery, M. R. .
ONCOGENE, 2016, 35 (04) :403-414
[4]   The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells [J].
Adamo, Patricia ;
Porazinski, Sean ;
Rajatileka, Shavanthi ;
Jumbe, Samantha ;
Hagen, Rachel ;
Cheung, Man-Kim ;
Wilson, Ian ;
Ladomery, Michael R. .
ONCOLOGY LETTERS, 2017, 14 (05) :5605-5610
[5]  
Adem C, 2001, ARCH PATHOL LAB MED, V125, P1562
[6]   An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas† [J].
Agulnik, M. ;
Yarber, J. L. ;
Okuno, S. H. ;
von Mehren, M. ;
Jovanovic, B. D. ;
Brockstein, B. E. ;
Evens, A. M. ;
Benjamin, R. S. .
ANNALS OF ONCOLOGY, 2013, 24 (01) :257-263
[7]  
Agulnik M, 2020, J CLIN ONCOL, V38
[8]  
Al-Abbadi MA, 2007, ARCH PATHOL LAB MED, V131, P288
[9]   PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis [J].
Alqahtani, Ali ;
Ayesh, Hazem S. K. ;
Halawani, Hafez .
CANCERS, 2020, 12 (01)
[10]   Observations on angiopoietin 2 in patients with angiosarcoma [J].
Amo, Y ;
Masuzawa, M ;
Hamada, Y ;
Katsuoka, K .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (05) :1028-1029